Jordan D. Berlin, M.D.

Faculty Appointments
Professor of Medicine Ingram Professor of Cancer Research
M.D., medicine, University of Illinois, Chicago, IllinoisB.S., biochemistry, University of Illinois, College of Medicine, Urbana-Champaign, Illinois
Office Address
797 Preston Research Building
Nashville, TN 37232-6307
Chan E, Goff LW, Cardin DB, Ancell K, Smith SJ, Whisenant JG, Ye F, Berlin JD. Phase II study of the Multikinase inhibitor of angiogenesis, Linifanib, in patients with metastatic and refractory colorectal cancer expressing mutated KRAS. Invest New Drugs [print-electronic]. 2017 Aug; 35(4): 491-8. PMID: 28353122, PII: 10.1007/s10637-017-0458-8, DOI: 10.1007/s10637-017-0458-8, ISSN: 1573-0646.

Lieu CH, Hidalgo M, Berlin JD, Ko AH, Cervantes A, LoRusso P, Gerber DE, Eder JP, Eckhardt SG, Kapp AV, Tsuhako A, McCall B, Pirzkall A, Uyei A, Tabernero J. A Phase Ib Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Cobimetinib and Duligotuzumab in Patients with Previously Treated Locally Advanced or Metastatic Cancers with Mutant KRAS. Oncologist [print-electronic]. 2017 Jun 6/7/2017; PMID: 28592615, PII: theoncologist.2017-0175, DOI: 10.1634/theoncologist.2017-0175, ISSN: 1549-490X.

Frankel AE, Flaherty KT, Weiner GJ, Chen R, Azad NS, Pishvaian MJ, Thompson JA, Taylor MH, Mahadevan D, Lockhart AC, Vaishampayan UN, Berlin JD, Smith DC, Sarantopoulos J, Riese M, Saleh MN, Ahn C, Frenkel EP. Academic Cancer Center Phase I Program Development. Oncologist [print-electronic]. 2017 Apr; 22(4): 369-74. PMID: 28314841, PMCID: PMC5388388, PII: theoncologist.2016-0409, DOI: 10.1634/theoncologist.2016-0409, ISSN: 1549-490X.

Tolcher AW, Berlin JD, Cosaert J, Kauh J, Chan E, Piha-Paul SA, Amaya A, Tang S, Driscoll K, Kimbung R, Kambhampati SR, Gueorguieva I, Hong DS. A phase 1 study of anti-TGFß receptor type-II monoclonal antibody LY3022859 in patients with advanced solid tumors. Cancer Chemother. Pharmacol [print-electronic]. 2017 Apr; 79(4): 673-80. PMID: 28280971, PII: 10.1007/s00280-017-3245-5, DOI: 10.1007/s00280-017-3245-5, ISSN: 1432-0843.

Cardin DB, Thota R, Goff LW, Berlin JD, Jones CM, Ayers GD, Whisenant JG, Chan E. A Phase II Study of Ganetespib as Second-line or Third-line Therapy for Metastatic Pancreatic Cancer. Am. J. Clin. Oncol [print-electronic]. 2017 Mar 3/15/2017; PMID: 28301350, DOI: 10.1097/COC.0000000000000377, ISSN: 1537-453X.

Thota R, Maitra A, Berlin JD. Preclinical Rationale for the Phase III Trials in Metastatic Pancreatic Cancer: Is Wishful Thinking Clouding Successful Drug Development for Pancreatic Cancer?. Pancreas. 2017 Feb; 46(2): 143-50. PMID: 28085753, PMCID: PMC5242389, PII: 00006676-201702000-00002, DOI: 10.1097/MPA.0000000000000753, ISSN: 1536-4828.

Rahib L, Fleshman JM, Matrisian LM, Berlin JD. Evaluation of Pancreatic Cancer Clinical Trials and Benchmarks for Clinically Meaningful Future Trials: A Systematic Review. JAMA Oncol. 2016 Sep 9/1/2016; 2(9): 1209-16. PMID: 27270617, PII: 2527367, DOI: 10.1001/jamaoncol.2016.0585, ISSN: 2374-2445.

Chan E, Arlinghaus LR, Cardin DB, Goff L, Berlin JD, Parikh A, Abramson RG, Yankeelov TE, Hiebert S, Merchant N, Bhaskara S, Chakravarthy AB. Phase I trial of vorinostat added to chemoradiation with capecitabine in pancreatic cancer. Radiother Oncol [print-electronic]. 2016 May; 119(2): 312-8. PMID: 27106554, PMCID: PMC4961249, PII: S0167-8140(16)31047-7, DOI: 10.1016/j.radonc.2016.04.013, ISSN: 1879-0887.

Goff LW, Cohen RB, Berlin JD, de Braud FG, Lyshchik A, Noberasco C, Bertolini F, Carpentieri M, Stampino CG, Abbattista A, Wang E, Borghaei H. A Phase I Study of the Anti-Activin Receptor-Like Kinase 1 (ALK-1) Monoclonal Antibody PF-03446962 in Patients with Advanced Solid Tumors. Clin. Cancer Res [print-electronic]. 2016 May 5/1/2016; 22(9): 2146-54. PMID: 26655846, PII: 1078-0432.CCR-15-1622, DOI: 10.1158/1078-0432.CCR-15-1622, ISSN: 1078-0432.

Matrisian LM, Berlin JD. The Past, Present, and Future of Pancreatic Cancer Clinical Trials. Am Soc Clin Oncol Educ Book. 2016; 35: e205-15. PMID: 27249725, PII: 159117, DOI: 10.14694/EDBK_159117, ISSN: 1548-8756.

Johnson DB, Dahlman KH, Knol J, Gilbert J, Puzanov I, Means-Powell J, Balko JM, Lovly CM, Murphy BA, Goff LW, Abramson VG, Crispens MA, Mayer IA, Berlin JD, Horn L, Keedy VL, Reddy NM, Arteaga CL, Sosman JA, Pao W. Enabling a genetically informed approach to cancer medicine: a retrospective evaluation of the impact of comprehensive tumor profiling using a targeted next-generation sequencing panel. Oncologist [print-electronic]. 2014 Jun; 19(6): 616-22. PMID: 24797823, PMCID: PMC4041676, PII: theoncologist.2014-0011, DOI: 10.1634/theoncologist.2014-0011, ISSN: 1549-490X.

Ellis LM, Bernstein DS, Voest EE, Berlin JD, Sargent D, Cortazar P, Garrett-Mayer E, Herbst RS, Lilenbaum RC, Sima C, Venook AP, Gonen M, Schilsky RL, Meropol NJ, Schnipper LE. American Society of Clinical Oncology perspective: Raising the bar for clinical trials by defining clinically meaningful outcomes. J. Clin. Oncol [print-electronic]. 2014 Apr 4/20/2014; 32(12): 1277-80. PMID: 24638016, PII: JCO.2013.53.8009, DOI: 10.1200/JCO.2013.53.8009, ISSN: 1527-7755.

Goff LW, Thakkar N, Du L, Chan E, Tan BR, Cardin DB, McLeod HL, Berlin JD, Zehnbauer B, Fournier C, Picus J, Wang-Gillam A, Lee W, Lockhart AC. Thymidylate synthase genotype-directed chemotherapy for patients with gastric and gastroesophageal junction cancers. PLoS ONE. 2014; 9(9): e107424. PMID: 25232828, PMCID: PMC4169411, PII: PONE-D-14-22736, DOI: 10.1371/journal.pone.0107424, ISSN: 1932-6203.

Cardin DB, Berlin JD. Pancreas cancer on the rise: are we up to the challenge? [editorial]. J. Natl. Cancer Inst [print-electronic]. 2013 Nov 11/20/2013; 105(22): 1675-6. PMID: 24203986, PII: djt316, DOI: 10.1093/jnci/djt316, ISSN: 1460-2105.

Goff LW, Benson AB, LoRusso PM, Tan AR, Berlin JD, Denis LJ, Benner RJ, Yin D, Rothenberg ML. Phase I study of oral irinotecan as a single-agent and given sequentially with capecitabine. Invest New Drugs [print-electronic]. 2012 Feb; 30(1): 290-8. PMID: 20857171, DOI: 10.1007/s10637-010-9528-x, ISSN: 1573-0646.

Goff LW, Berlin JD. Advanced biliary tract cancers. Am Soc Clin Oncol Educ Book. 2012; 281-2. PMID: 24451749, PII: 203, DOI: 10.14694/EdBook_AM.2012.32.281, ISSN: 1548-8748.

Chan E, Lafleur B, Rothenberg ML, Merchant N, Lockhart AC, Trivedi B, Chung CH, Coffey RJ, Berlin JD. Dual blockade of the EGFR and COX-2 pathways: a phase II trial of cetuximab and celecoxib in patients with chemotherapy refractory metastatic colorectal cancer. Am. J. Clin. Oncol. 2011 Dec; 34(6): 581-6. PMID: 21217396, PMCID: PMC3133812, DOI: 10.1097/COC.0b013e3181fe46a1, ISSN: 1537-453X.

Puzanov I, Lee W, Chen AP, Calcutt MW, Hachey DL, Vermeulen WL, Spanswick VJ, Liao CY, Hartley JA, Berlin JD, Rothenberg ML. Phase I pharmacokinetic and pharmacodynamic study of SJG-136, a novel DNA sequence selective minor groove cross-linking agent, in advanced solid tumors. Clin. Cancer Res [print-electronic]. 2011 Jun 6/1/2011; 17(11): 3794-802. PMID: 21346148, PMCID: PMC3107910, PII: 1078-0432.CCR-10-2056, DOI: 10.1158/1078-0432.CCR-10-2056, ISSN: 1078-0432.

Castellanos EH, Cardin DB, Berlin JD. Treatment of early-stage pancreatic cancer. Oncology (Williston Park, N.Y.). 2011 Feb; 25(2): 182-9. PMID: 21456390, PII: 167379, ISSN: 0890-9091.

Backlund DC, Berlin JD, Parikh AA. Update on adjuvant trials for pancreatic cancer. Surg. Oncol. Clin. N. Am. 2010 Apr; 19(2): 391-409. PMID: 20159521, PII: S1055-3207(09)00118-5, DOI: 10.1016/j.soc.2009.11.003, ISSN: 1558-5042.

Strickland SA, Berlin JD. Hiccups: underappreciated and underrecognized. J Support Oncol. 2009 Jul; 7(4): 128-9. PMID: 19731576, ISSN: 1544-6794.

Goff LW, Rothenberg ML, Lockhart AC, Roth BJ, VerMeulen WL, Chan E, Berlin JD. A phase I trial of irinotecan alternating with epirubicin in patients with advanced malignancies. Am. J. Clin. Oncol. 2008 Oct; 31(5): 413-6. PMID: 18838875, PII: 00000421-200810000-00002, DOI: 10.1097/COC.0b013e318168ef2a, ISSN: 1537-453X.

Stover DG, Lockhart AC, Berlin JD, Chan E, Sandler AB, Sosman JA, Middlebrook V, Nicol S, Rothenberg ML. Phase I trial of pemetrexed plus oxaliplatin administered every other week in patients with metastatic cancer. Invest New Drugs [print-electronic]. 2008 Aug; 26(4): 339-45. PMID: 18463792, DOI: 10.1007/s10637-008-9133-4, ISSN: 0167-6997.

Bauer TM, Berlin JD. A 17 year-old man with an exon 11 mutation of CD-117 causing a gastrointestinal stromal tumor. Cancer Invest. 2008 Mar; 26(2): 182-4. PMID: 18259950, PII: 788770048, DOI: 10.1080/07357900701637824, ISSN: 1532-4192.

Berlin JD, Venook A, Bergsland E, Rothenberg M, Lockhart AC, Rosen L. Phase II trial of T138067, a novel microtubule inhibitor, in patients with metastatic, refractory colorectal carcinoma. Clin Colorectal Cancer. 2008 Jan; 7(1): 44-7. PMID: 18279576, PII: S1533-0028(11)70396-6, DOI: 10.3816/CCC.2008.n.006, ISSN: 1533-0028.

Chan E, Berlin JD. Controversies in the adjuvant treatment of pancreas cancer: a lack of knowledge or simply a lack of will?. Gastrointest Cancer Res. 2007 Sep; 1(5): 204-6. PMID: 19262710, PMCID: PMC2632532, ISSN: 1934-7820.

Berlin JD. Adjuvant therapy for pancreatic cancer: to treat or not to treat?. Oncology (Williston Park, N.Y.). 2007 May; 21(6): 712-8; discussion 720, 725. PMID: 17564327, PII: 169590, ISSN: 0890-9091.

Lockhart AC, Cropp GF, Berlin JD, Donnelly E, Schumaker RD, Schaaf LJ, Hande KR, Fleischer AC, Hannah AL, Rothenberg ML. Phase I/pilot study of SU5416 (semaxinib) in combination with irinotecan/bolus 5-FU/LV (IFL) in patients with metastatic colorectal cancer. Am. J. Clin. Oncol. 2006 Apr; 29(2): 109-15. PMID: 16601426, PII: 00000421-200604000-00001, DOI: 10.1097/, ISSN: 1537-453X.

Rothenberg ML, LaFleur B, Levy DE, Washington MK, Morgan-Meadows SL, Ramanathan RK, Berlin JD, Benson AB, Coffey RJ. Randomized phase II trial of the clinical and biological effects of two dose levels of gefitinib in patients with recurrent colorectal adenocarcinoma. J. Clin. Oncol. 2005 Dec 12/20/2005; 23(36): 9265-74. PMID: 16361624, PII: 23/36/9265, DOI: 10.1200/JCO.2005.03.0536, ISSN: 0732-183X.

Lockhart AC, Rothenberg ML, Berlin JD. Treatment for pancreatic cancer: current therapy and continued progress. Gastroenterology. 2005 May; 128(6): 1642-54. PMID: 15887156, PII: S0016508505004658, ISSN: 0016-5085.

Lockhart AC, Berlin JD. The epidermal growth factor receptor as a target for colorectal cancer therapy. Semin. Oncol. 2005 Feb; 32(1): 52-60. PMID: 15726506, PII: S0093775404004658, DOI: 10.1053/j.seminoncol.2004.09.036, ISSN: 0093-7754.

Tedesco KL, Lockhart AC, Berlin JD. The epidermal growth factor receptor as a target for gastrointestinal cancer therapy. Curr Treat Options Oncol. 2004 Oct; 5(5): 393-403. PMID: 15341677, ISSN: 1527-2729.

Berlin JD. Current and future strategies for treating metastatic pancreatic cancer. Clin Adv Hematol Oncol. 2004 Aug; 2(8): 510-2. PMID: 16163230, ISSN: 1543-0790.

Lockhart AC, Howard M, Hande KR, Roth BJ, Berlin JD, Vreeland F, Campbell A, Fontana E, Fiorentini F, Fowst C, Paty VA, Lankford O, Rothenberg ML. A phase I dose-escalation and pharmacokinetic study of brostallicin (PNU-166196A), a novel DNA minor groove binder, in adult patients with advanced solid tumors. Clin. Cancer Res. 2004 Jan 1/15/2004; 10(2): 468-75. PMID: 14760067, ISSN: 1078-0432.

Rothenberg ML, Oza AM, Bigelow RH, Berlin JD, Marshall JL, Ramanathan RK, Hart LL, Gupta S, Garay CA, Burger BG, Le Bail N, Haller DG. Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. J. Clin. Oncol. 2003 Jun 6/1/2003; 21(11): 2059-69. PMID: 12775730, PII: JCO.2003.11.126, DOI: 10.1200/JCO.2003.11.126, ISSN: 0732-183X.

Berlin JD, Rothenberg ML. Chemotherapeutic advances in pancreatic cancer. Curr Oncol Rep. 2003 May; 5(3): 219-26. PMID: 12667419, ISSN: 1523-3790.

Meadows SM, Mulkerin D, Berlin J, Kolesar J, Warren D, Thomas JP. Phase II Trial of Perillyl Alcohol in Patients with Metastatic Colorectal Cancer. International Journal GI Cancer. 2003; ((In Press)).

Rothenberg M, Oza AM, Bigelow RH, Berlin JD, Marshall J, Ramanathan RK, Hart LL, Gupta S, Garay CA, Burger BG, Le Bail N, Haller DG. Superiority of Oxaliplatin + Bolus & Infusional 5-FU/Leucovorin Over Either Therapy Alone in Patients with Progressive Colorectal Cancer Following Irinotecan + Bolus 5-FU/Leucovorin: Interim Results of a Phase III Trial. J Clin Oncology. 2003; ((In Press)).

Berlin JD, Rothenberg ML. Chemotherapeutic Advances in Pancreatic Cancer. Curr Oncol Rep. 2003; ((In Press)).

Berlin JD. Targeting vascular endothelial growth factor in colorectal cancer. Oncology (Williston Park, N.Y.). 2002 Aug; 16(8 Suppl 7): 13-5. PMID: 12199627, PII: 175171, ISSN: 0890-9091.

Berlin JD, Catalano P, Thomas JP, Kugler JW, Haller DG, Benson AB. Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J. Clin. Oncol. 2002 Aug 8/1/2002; 20(15): 3270-5. PMID: 12149301, DOI: 10.1200/JCO.2002.11.149, ISSN: 0732-183X.

Liu G, Berlin J, Tutsch KD, Van Ummersen L, Dresen A, Marnocha R, Arzoomanian R, Alberti D, Feierabend C, Binger K, and Wilding G. Phase I Clinical and Pharmacokinetic Study of Oral Penclomedine (NSC 338720) in Adults with Advanced Solid Malignancy. Clin Cancer Res. 2002; ((8)): 706-11.

Berlin JD. Targeting Vascular Endothelial Growth Factor in Colon Cancer. Oncology. 2002; ((16)): 13-5.

Berlin JD, Tutsch KD, Arzoomanian RZ, Alberti D, Binger, Feierabend C, Dresen A, Marnocha R, Pluda J, and Wilding G. Phase I and Pharmacokinetic Study of a Micronized Formulation of Carboxyamidotriazole (CAI), a Calcium Signal Transduction Inhibitor: Toxicity, Bioavailability and the Effect of Food. Clin Cancer Res. 2002; ((8)): 86-94.

Berlin JD, Catalano P, Thomas JP, Kugler JW, Haller DG and Benson III AB. Phase III Study of Gemcitabine in Combination with Fluorouracil Versus Gemcitabine Alone in Patients with Advanced Pancreatic Carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Onc. 2002; ((20)): 3270-5.

Meadows S, Thomas JP, Mulkerin D, Berlin JD, Bailey H, Binger K, Volkman J, Alberti D, Feierabend C, Marrocha R, Arzoomanian RZ, Wilding G. Phase I study of Eniluracil, Oral 5-Fluorouracil and Gemcitabine in Patients with Advanced Malignancy. Inv New Drugs. 2002; ((20)): 377-87.

Berlin JD, Rothenberg M. Chemotherapy for resectable and advanced pancreatic cancer. Oncology (Williston Park, N.Y.). 2001 Oct; 15(10): 1241-9, 1254; discussion 1254. PMID: 11702956, PII: 171548, ISSN: 0890-9091.

Berlin JD. New Directions in the Treatment of Advanced Colorectal Cancer. Oncology. 2001; ((15)): 27-30.

Blanke CD, Haller DG, Benson AB, Rothenberg ML, Berlin J, Mori M, Hsieh Y, Miller LL. A Phase II Study of Irinotecan with 5-fluorouracil and Leucovorinin Patients with Previously Untreated Gastric Adenocarcinoma. Ann Oncol. 2001; ((12)): 1575-80.

Berlin JD, Rothenberg ML. Chemotherapy for Resectable and Advanced Pancratic Cancer. Oncology. 2001; ((15)): 1241-48.

Berlin JD, Adak S, Vaughn DJ, Flinker D, Blaszkowsky L, Harris JE, Benson IIIAB. A phase II study of gemcitabine and 5-fluorouracil in metastatic pancreatic cancer: an Eastern Cooperative Oncology Group Study (E3296). Oncology. 2000 Apr; 58(3): 215-8. PMID: 10765123, PII: 12103, DOI: 12103, ISSN: 0030-2414.

Berlin JD. Second-Line Therapy in Colorectal Cancer. Oncology. 2000; ((14)): 21-6.

Berlin J, Adak S, Vaughn DJ, Flinker D, Blaszkowsky L, Harris JE, and Benson III AB. A Phase II Study of Gemcitabine and 5-Fluorouracil in Metastatic Pancreatic Cancer: An Eastern Cooperative Oncology Group Study (E3296). Oncology. 2000; ((58)): 215-8.

Talamonti MS, Catalano PJ, Vaughn DJ, Whittington R, Beauchamp RD, Berlin J, Benson III AB. An ECOG Phase I Trial of Protracted Venous Infusion 5-fluorouracil Plus Weekly Gemcitabine With Concurrent Radiation Therapy in Patients with Locally Advanced Pancreas Cancer: A Regimen With Unexpected Early Toxicity. J Clin Onc. 2000; ((18)): 3384-9.

Berlin J. Gemcitabine. Clinical Perspectives in Gastroenterology. 1999; ((2)): 106-11.

Berlin J, Merrick HW, Smith TJ, Lerner H. Phase II Evaluation of Treatment of Hepatic Metastases from Colorectal Cancer and Adjuvant Hepatic Arterial Infusion of Floxuridine: An Eastern Cooperative Oncology GroupStudy (PB083). Am J Clin Oncol (CCT). 1999; 3((22)): 291-3.

Berlin J, Alberti D, Arzoomanian R, Feierabend C, Simon K, Morgan K, and Wilding G. A Phase I Study of Gemcitabine, 5-fluorouracil and Leucovorin in Patients with Advanced, Recurrent, and/or Metastatic Solid Tumors. Invest New Drugs. 1999; ((16)): 325-30.

Kolesar JK, Johnson C, Freeberg BL, Berlin JD, and Schiller JH. Warfarin-5FU Drug Interaction-A Consecutive Case Series. Pharmacotherapy. 1999; 12((19)): 1445-49.

Berlin J, Propert K, Trump D, Wilding G, Hudes G, Glick J, Burch P, Keller A, Loehrer P. Phase II Study of 5-Fluorouracil and Leucovorin Therapy in Patients with Hormone Refractory Prostate Cancer: An Eastern Cooperative Oncology Group Study (E1889). Amer J Clin Oncol-Cancer Clin Trials. 1998; ((21)): 171-6.

Berlin J, Theisen J, Marnocha R. Gemcitabine (Gemzar) (7) CanceRx7. On Drugs and Therapeutics. 1998; ((1)): 202-4.

Berlin J, Stewart JA, Storer B, Tutsch KD, Arzoomanian RZ, Alberti D, Feierabend C, Simon K, and Wilding G. Phase I Cliical and Pharmacokinetic Trial of Penclomedine Utilizing a Novel, Two-Stage Trial Design. J Clin Oncol. 1998; ((16)): 1142-9.

Berlin J, Tutsch KD, Hutson P, Cleary J, Rago RP, Zoomanian RZ, Alberti D, Feierabend C, Wilding G. Phase I Clinical and Pharmacokinetic Study of Oral Carboxyamidotriazole (CAI), a Signal Transduction Inhibitor. J Clin Oncol. 1997; ((15)): 781-9.

Schiller JH, Storer B, Berlin J, Wittenkeller J, Larson M, Pharo L, Berry W. Amifostine, Cisplatin and Vinblastine in Metastatic Nonsmall Cell Lung Cancer: A Report of High Response Rates and Prolonged Survival. J Clin Oncol. 1996; 14: 1913-21.

Berlin J, King AC, Tutsch K, Findlay JW, Kohler P, Collier M, Clendennin NJ, Wilding G. A Phase II study of vinblastine in combination with acrivastine in patients with advanced renal cell carcinoma. Invest New Drugs. 1994; 12: 137-41.